Climb Bio
CompanyUnited States
Climb Bio develops one asset, in phase 2 (budoprutug in primary membranous nephropathy). Mostly antibody acting on CD19; based in the United States.
- 1
- Asset
- Furthest stage
- Phase 2
- 1
- Trial
- 1
- Signal
Pipeline
1Anti-CD19 monoclonal antibody that depletes B cells to reduce pathogenic autoantibody production.
Phase 2, Antibody, CD19, primary membranous nephropathy
Full company profiles: pipeline, trials, funding and people.
In the full profile
- Evidence behind the mechanisms1
- Trials1
- Signals1
- Similar companies6